Scott A. Kelly - Nov 28, 2022 Form 4 Insider Report for CytoDyn Inc. (CYDY)

Role
CMO
Signature
/s/ Antonio Migliarese, Attorney-In-Fact
Stock symbol
CYDY
Transactions as of
Nov 28, 2022
Transactions value $
$0
Form type
4
Date filed
11/30/2022, 07:33 PM
Previous filing
Nov 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYDY Common Stock Award $0 +16.9K +0.78% $0.00 2.18M Nov 30, 2022 Direct F1
holding CYDY Common Stock 782K Nov 28, 2022 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYDY Non-qualified stock option (right to buy) Award $0 +2.32M $0.00 2.32M Nov 28, 2022 Common Stock 2.32M $0.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary.
F2 241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026.